Stoke Therapeutics, Inc. 8-K

What Happened
Stoke Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026, by issuing a press release dated May 7, 2026 and filed an 8‑K under Item 2.02 (Results of Operations and Financial Condition) to disclose the update.

Key Details

• Press release dated May 7, 2026 announced quarterly results for the period ended March 31, 2026.
• The Form 8‑K was filed under Item 2.02 (Results of Operations and Financial Condition).
• Exhibit 99.1 to the filing is the press release; the report was signed by CFO Thomas E. Leggett on May 7, 2026.

Why It Matters
Quarterly results provide investors with updated information on Stoke’s revenue, expenses and cash position and can affect near‑term valuation and investor expectations. Retail investors should read the attached press release for the specific numbers and await the company’s subsequent 10‑Q for full financial statements and more detailed commentary.